Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China.
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China.
Int Immunopharmacol. 2024 Dec 25;143(Pt 1):113383. doi: 10.1016/j.intimp.2024.113383. Epub 2024 Oct 14.
Although efficacy and safety of Upadacitinib and Dupilumab in moderate to severe atopic dermatitis (AD) have been shown in clinical trials, real world data are still limited. The aim of this retrospective study is to indirectly compare the efficacy and safety of Upadacitinib and Dupilumab in patients with moderate to severe AD in real world practice.
A single-center retrospective cohort study was conducted. The study included patients with moderate to severe AD, who were enrolled from May 2022 to March 2024, to indirectly compare the efficacy and safety of Upadacitinib and Dupilumab over 12 weeks duration.
Eighty-seven patients were included (46 received Upadacitinib and 41 Dupilumab). Compared with week 0, there was a significant decrease in EASI score, ADCT score and NRS score in patients of both groups in weeks 4, 8, and 12. In week 4, the reduction in EASI score, ADCT score and NRS score was significantly greater in patients of Upadacitinib group compared to those in Dupilumab group. Compared to baseline, in week 12, the decrease in IL-4, IL-13, and IL-31 level in the serum of patients in Upadacitinib group was significantly greater than that of patients in Dupilumab group. The total IgE of patients in Dupilumab group decreased significantly, while there was no significant change in patients of Upadacitinib group. Although Upadacitinib group reported more adverse events than Dupilumab group, no serious adverse events were observed.
Both Upadacitinib and Dupilumab groups showed effective trend in patients with moderate to severe AD. Upadacitinib has better efficacy and rapid onset in the treatment of patients with moderate to severe AD.
尽管乌帕替尼和度普利尤单抗在中重度特应性皮炎（AD）的临床试验中已显示出疗效和安全性，但真实世界的数据仍然有限。本回顾性研究旨在间接比较乌帕替尼和度普利尤单抗在真实世界实践中治疗中重度 AD 患者的疗效和安全性。
进行了一项单中心回顾性队列研究。该研究纳入了 2022 年 5 月至 2024 年 3 月期间中度至重度 AD 患者，以间接比较乌帕替尼和度普利尤单抗在 12 周治疗期间的疗效和安全性。
共纳入 87 例患者（46 例接受乌帕替尼治疗，41 例接受度普利尤单抗治疗）。与治疗前相比，两组患者在第 4、8 和 12 周时 EASI 评分、ADCT 评分和 NRS 评分均显著降低。第 4 周时，乌帕替尼组患者 EASI 评分、ADCT 评分和 NRS 评分的降低幅度明显大于度普利尤单抗组。与基线相比，第 12 周时，乌帕替尼组患者血清中 IL-4、IL-13 和 IL-31 水平的降低幅度明显大于度普利尤单抗组。度普利尤单抗组患者的总 IgE 显著降低，而乌帕替尼组患者的总 IgE 无明显变化。乌帕替尼组报告的不良事件多于度普利尤单抗组，但均无严重不良事件发生。
乌帕替尼和度普利尤单抗组在中重度 AD 患者中均显示出有效趋势。乌帕替尼治疗中重度 AD 患者的疗效更好，起效更快。
